In exchange for the multimillion dollar cash payout, Edwards Lifesciences Corp. announced Monday that it had granted certain nonexclusive licenses to Medtronic for devices used to treat late-stage cardiovascular disease.

The settlement marks the end of an infringement battle that began in August 2003, though the number pales in comparison to the record-breaking $1.4 billion...